Board of Directors

Dennis Condon

Dennis Condon
Chairman of the Board

Dennis Condon is currently a member of the Audit and Risk Committee and the Remuneration and Nomination Committee, as well as CEO and President of Nuvesse Skin Therapies, a venture-backed cosmeceutical skincare company that has launched 12 products into the US medical device market. He was formerly CEO and President of Merz Aesthetics, Inc. (from September 2011 to January 2013), after serving as President and Chief Business Officer from July 2007 and a board member from 2004 to 2007. Additionally, Mr. Condon was the former CEO of BioForm Medical (acquired by Merz Aesthetic for US$250 million).

Mr. Condon carries 30 years of experience in key executive roles in the plastic surgery market, including serving as the President and CEO of Mentor Aesthetics, one of the two largest global breast implant manufacturers.

Ron Eastman
Board Member

Ron Eastman is a Managing Director at EW Healthcare Partners (formerly Essex Woodlands) in Palo Alto, CA. Having over 35 years of experience in building healthcare businesses, Ron began his career at American Cyanamid Company. There he managed pharmaceutical products, divisions and subsidiaries in the U.S. and overseas, and has since helped build three private healthcare companies—Geron, HCORP, and Rinat Neuroscience.

Under his leadership, Geron became a cutting-edge biotech company growing from a venture-backed startup to a publicly traded pioneer in regenerative medicine and cancer treatment. HCORP established itself as the leader in hospital-based, interactive patient services, and was sold to a diversified competitor. At Rinat, Ron led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500 million in 2006.

Mr. Eastman serves on the boards of Corium International, EluSys Therapeutics, Inc. and IntegenX Inc.

Ron Eastman
Brian Chee

Brian Chee
Board Member

Brian Chee is a general partner of Polaris Partners, with a primary focus on investments in healthcare and technology companies. Mr. Chee’s vast board experience incorporates currently serving on the boards of Bohola, Data Sciences, Ella Health, Medvantx, and US HealthVest. Mr. Chee received his M.B.A. from the Tuck School of Business at Dartmouth, and his B.S. from the U.S. Military Academy at West Point. Prior to joining Polaris in 1996, Mr. Chee attained significant business operations and leadership expertise with Baxter Healthcare, a global, diversified healthcare company with expertise in medical devices, pharmaceuticals and biotechnology.

Warren D. Cooper
Board Member

Warren D. Cooper is a UK-trained physician with over 35 years of experience in the global pharmaceutical industry. Dr. Cooper is Chief Medical Officer, Head of Portfolio Management Committee, and Partner at HealthCare Royalty Partners (HCR). He also serves as the lead outside director of Zynerba Pharmaceuticals. With a background in cardiology and cardiac surgery, he spent 12 years with Merck in various positions, ultimately becoming the head of worldwide clinical research operations for Merck Research Laboratories. At AstraZeneca PLC, he led the company’s cardiovascular business division, responsible for everything from in-licensing and development, to commercialization. He was the founding CEO of Prism Pharmaceuticals, a specialty pharmaceutical company that he led from inception to the sale of the company to Baxter International.

Dr. Cooper holds degrees in physiology, medicine, and surgery from The London Hospital (University of London) and is a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, and of the International Society of Hypertension.

Warren D. Cooper
Vince Ippolito

Vince Ippolito
Board Member

Vince Ippolito has over 30 years of experience in the pharmaceuticals industry, including 20 years in dermatology and aesthetic medicine. He most recently served as the Chief Commercial Officer Executive Vice President of Anacor Pharmaceuticals until Sept 2017, where he was responsible for developing marketing and sales functions, as well as strategizing the company’s product portfolio. Previously, Mr. Ippolito was Executive Vice President and Chief Commercial Officer at Medicis, a leading dermatology and aesthetic medicine company, who brought Restylane and Dysport to Market in the US.  Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine.  He took a leading role in two of the largest dermatology acquisitions in the past five years totaling $7.8 billion.

Mr. Ippolito holds a B.A. in Business Administration, Management, and Operations from the University of Wisconsin and a minor in East Asian Studies from Sophia University in Japan.

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.